The global market for APIs is significant and continues to grow, driven by an increasing demand for new drugs and innovations in biotechnology. The rise of personalized medicine, where treatments are tailored to individual genetic profiles, further emphasizes the need for advanced API development.
One of the primary benefits of pentoxifylline is its relatively favorable safety profile. Unlike some other pharmacological agents, it is associated with fewer side effects, making it suitable for a wider patient population, including those who may have contraindications to more potent drugs. However, it is essential for patients to be monitored as gastrointestinal disturbances, such as nausea and diarrhea, can occur, although most are mild and self-limiting.